Brand Institute announced its work with Celltrion Healthcare in developing the brand name VEGZELMA®, which was approved by the FDA on September 27, 2022. As a product, VEGZELMA® (bevacizumab-adcd) is the fourth bevacizumab biosimilar currently approved in the United States. VEGZELMA® is indicated for the treatment of patients with: Metastatic colorectal cancer; Recurrent or metastatic non-squamous non-small cell lung cancer; Recurrent glioblastoma; Metastatic renal cell carcinoma; Persistent, recurrent, or metastatic cervical cancer; and Epithelial ovarian, fallopian tube, or primary peritoneal cancer.
1st Jan change | Capi. | |
---|---|---|
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-11.47% | 33.49B | |
-19.34% | 14.62B | |
-8.95% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |